Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer : the EUELC cohort
Scoccianti, Chiara, Vesin, Aurelien, Martel, Ghislaine, Olivier, Magali, Brambilla, Elisabeth, Timsit, Jean-Francois, Tavecchio, Luca, Brambilla, Christian, Field, John K., Hainaut, Pierre, European Early Lung Cancer Consortium, & O'Byrne, Kenneth J. (2012) Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer : the EUELC cohort. The European Respiratory Journal, 40(1), pp. 177-184.
Nonsmall cell lung cancer samples from the European Early Lung Cancer biobank were analysed to assess the prognostic significance of mutations in the TP53, KRAS and EGFR genes. The series included 11 never-smokers, 86 former smokers, 152 current smokers and one patient without informed smoking status. There were 110 squamous cell carcinomas (SCCs), 133 adenocarcinomas (ADCs) and seven large cell carcinomas or mixed histologies. Expression of p53 was analysed by immunohistochemistry. DNA was extracted from frozen tumour tissues. TP53 mutations were detected in 48.8% of cases and were more frequent among SCCs than ADCs (p<0.0001). TP53 mutation status was not associated with prognosis. G to T transversions, known to be associated with smoking, were marginally more common among patients who developed a second primary lung cancer or recurrence/metastasis (progressive disease). EGFR mutations were almost exclusively found in never-smoking females (p=0.0067). KRAS mutations were detected in 18.5% of cases, mainly ADC (p<0.0001), and showed a tendency toward association with progressive disease status. These results suggest that mutations are good markers of different aetiologies and histopathological forms of lung cancers but have little prognostic value, with the exception of KRAS mutation, which may have a prognostic value in ADC. Copyright©ERS 2012.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Additional Information:||Articles free to read on journal website after 18 months|
|Keywords:||EGFR, KRAS, Mutations, Nonsmall cell lung cancer, Prognosis, TP53, epidermal growth factor receptor, K ras protein, protein p53, adenocarcinoma, adult, aged, article, cancer growth, cancer prognosis, cancer recurrence, cohort analysis, DNA extraction, EGFR gene, Europe, European Early Lung Cancer, female, gene activity, gene expression, gene function, gene mutation, genetic association, histology, histopathology, human, human tissue, immunohistochemistry, KRAS gene, large cell carcinoma, lung non small cell cancer, major clinical study, male, oncogene, primary tumor, priority journal, smoking, squamous cell carcinoma, TP53 gene, Carcinoma, Non-Small-Cell Lung, Follow-Up Studies, Genes, erbB-1, Genes, p53, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins, ras Proteins, Survival Analysis, Tumor Suppressor Protein p53|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2012 European Respiratory Society|
|Deposited On:||13 Dec 2013 01:07|
|Last Modified:||03 Feb 2015 04:34|
Repository Staff Only: item control page